Actively Recruiting
FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Led by University Health Network, Toronto · Updated on 2026-03-05
64
Participants Needed
1
Research Sites
453 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
S
Sunnybrook Health Sciences Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer. The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.
CONDITIONS
Official Title
FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA
- Planned for radical radiotherapy and concurrent cisplatin chemotherapy
- Age 18 years or older
You will not qualify if you...
- Evidence of distant metastases (except suspicious paraaortic nodes below the renal vessels if included in radiation field)
- Previous anticancer treatment for cervical cancer
- Other cervical cancer tumor types such as small cell or serous carcinoma
- Contraindications to 18FDG PET-CT
- Contraindications to radiotherapy (e.g., severe Crohn's disease)
- Contraindications to chemotherapy (e.g., non-reversible renal failure)
- History of another invasive cancer except non-melanoma skin cancer or tumors treated with no evidence of disease for 5 or more years
- Known pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network, The Princess Margaret
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
K
Kathy Han, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here